Issue Date: July 16, 2012
Evotec Licenses Compounds To Janssen
Evotec, a German contract research organization, has licensed to Janssen Pharmaceuticals a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. The antidiabetes compounds were identified by scientists at Harvard University and analyzed by researchers at CureBeta, an R&D joint venture established last year by Evotec, Harvard, and Howard Hughes Medical Institute to develop disease-state-modifying therapeutic targets. Janssen, a division of Johnson & Johnson, will pay $8 million up front and could make milestone payments of up to $300 million per product.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society